|
Lotus Pharmaceuticals
|
 30/04/2010
[Company watch]
Lotus Pharma to commence asthma drug trial in China
Lotus Pharmaceuticals, a developer, manufacturer and seller of pharma products in China, reported that its asthma drug Laevo-Bambuterol has received approval to conduct clinical trials from China\'s State Food and Drug Administration (SFDA).
|
| |
|
Lotus Pharmaceuticals, a developer, manufacturer and seller of pharma products in China, reported that its asthma drug Laevo-Bambuterol has received approval to conduct clinical trials from China\'s State Food and Drug Administration (SFDA).
Bambuterol Hydrochloride tablets is categorized as a class 1 new drug. According to the company, the preclinical studies of Laevo-Bambuterol have shown that it is more effective and have lower toxicity than Bambuterol, a popular asthma drug currently on the market.
The company is communicating with experts from the SFDA\'s Drug Review and Evaluation Center on the designs for clinical trials and expects the new product to launch in 2013-2014.
Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical and En Ze Jia Shi Pharmaceutical. Lotus\' current drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. |
|
|
|
|
